Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1494MR)

This product GTTS-WQ1494MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1494MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8562MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ1902MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ8776MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ13773MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ13253MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11728MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ8263MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ9178MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW